The	O
effect	O
of	O
Nigella	B:C1140702
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
in	O
male	O
rats	O
.	O

The	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	B:C0021368
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
in	O
male	O
rats	O
.	O

The	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	B:C0151654
fibrosis	I:C0151654
in	O
male	O
rats	O
.	O

The	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
in	O
male	O
rats	B:C0086893
.	O

Nigella	B:C1140702
sativa	I:C1140702
(	O
Nigella	O
sativa	I:C1140702
)	O
(	O
Ranunculaceae	O
)	O
used	O
as	O
a	O
protective	O
and	O
therapeutic	O
traditional	O
medicine	I:C0025131
.	O

Nigella	O
sativa	I:C1140702
(	O
Nigella	B:C1140702
sativa	I:C1140702
)	O
(	O
Ranunculaceae	O
)	O
used	O
as	O
a	O
protective	O
and	O
therapeutic	O
traditional	O
medicine	I:C0025131
.	O

Nigella	O
sativa	I:C1140702
(	O
Nigella	O
sativa	I:C1140702
)	O
(	O
Ranunculaceae	B:C0446214
)	O
used	O
as	O
a	O
protective	O
and	O
therapeutic	O
traditional	O
medicine	I:C0025131
.	O

Nigella	O
sativa	I:C1140702
(	O
Nigella	O
sativa	I:C1140702
)	O
(	O
Ranunculaceae	O
)	O
used	O
as	O
a	O
protective	B:C0033613
and	O
therapeutic	O
traditional	O
medicine	I:C0025131
.	O

Nigella	O
sativa	I:C1140702
(	O
Nigella	O
sativa	I:C1140702
)	O
(	O
Ranunculaceae	O
)	O
used	O
as	O
a	O
protective	O
and	O
therapeutic	O
traditional	B:C0025131
medicine	I:C0025131
.	O

This	O
study	O
evaluates	B:C0220825
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	B:C1140702
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	B:C0021368
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	B:C0151654
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	B:C0229671
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	B:C0040300
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	B:C0242606
stress	I:C0242606
status	O
in	O
male	O
rats	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
Nigella	O
sativa	I:C1140702
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	I:C0151654
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	I:C0242606
status	O
in	O
male	O
rats	B:C0086893
.	O

Fifty	O
male	O
Wistar	B:C0034716
rats	I:C0034716
were	O
divided	O
into	O
five	O
groups	O
:	O
(	O
1	O
)	O
control	O
;	O
(	O
2	O
)	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
,	O
1	O
mg/kg/day	O
;	O
(	O
3	O
)	O
lipopolysaccharide	O
+	O

Fifty	O
male	O
Wistar	O
rats	I:C0034716
were	O
divided	O
into	O
five	O
groups	O
:	O
(	O
1	O
)	O
control	O
;	O
(	O
2	O
)	O
lipopolysaccharide	B:C0023810
(	O
lipopolysaccharide	O
)	O
,	O
1	O
mg/kg/day	O
;	O
(	O
3	O
)	O
lipopolysaccharide	O
+	O

Fifty	O
male	O
Wistar	O
rats	I:C0034716
were	O
divided	O
into	O
five	O
groups	O
:	O
(	O
1	O
)	O
control	O
;	O
(	O
2	O
)	O
lipopolysaccharide	O
(	O
lipopolysaccharide	B:C0023810
)	O
,	O
1	O
mg/kg/day	O
;	O
(	O
3	O
)	O
lipopolysaccharide	O
+	O

Fifty	O
male	O
Wistar	O
rats	I:C0034716
were	O
divided	O
into	O
five	O
groups	O
:	O
(	O
1	O
)	O
control	O
;	O
(	O
2	O
)	O
lipopolysaccharide	O
(	O
lipopolysaccharide	O
)	O
,	O
1	O
mg/kg/day	O
;	O
(	O
3	O
)	O
lipopolysaccharide	B:C0023810
+	O

Nigella	B:C1140702
sativa	I:C1140702
(	O
hydroalcoholic	O
extract	I:C0032081
)	O
,	O
100	O
mg/kg/day	O
;	O
(	O
4	O
)	O
lipopolysaccharide	O
+	O

Nigella	O
sativa	I:C1140702
(	O
hydroalcoholic	B:C0032081
extract	I:C0032081
)	O
,	O
100	O
mg/kg/day	O
;	O
(	O
4	O
)	O
lipopolysaccharide	O
+	O

Nigella	O
sativa	I:C1140702
(	O
hydroalcoholic	O
extract	I:C0032081
)	O
,	O
100	O
mg/kg/day	O
;	O
(	O
4	O
)	O
lipopolysaccharide	B:C0023810
+	O

Nigella	B:C1140702
sativa	I:C1140702
,	O
200	O
mg/kg/day	O
;	O
(	O
5	O
)	O
lipopolysaccharide	O
+	O

Nigella	O
sativa	I:C1140702
,	O
200	O
mg/kg/day	O
;	O
(	O
5	O
)	O
lipopolysaccharide	B:C0023810
+	O

Nigella	B:C1140702
sativa	I:C1140702
,	O
400	O
mg	O
/	O
kg	O
/	O
day	O
(	O
n	O
=	O
10	O
in	O
each	O
group	O
)	O
.	O

The	O
duration	O
of	O
lipopolysaccharide	B:C0023810
administration	O
was	O
two	O
weeks	O
.	O

The	O
duration	O
of	O
lipopolysaccharide	O
administration	B:C3469597
was	O
two	O
weeks	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	B:C0205664
,	O
blood	O
samples	I:C0178913
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	O
and	O
stained	O
for	O
histological	O
evaluation	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	B:C0178913
samples	I:C0178913
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	O
and	O
stained	O
for	O
histological	O
evaluation	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	I:C0178913
were	O
taken	O
and	O
ventricles	B:C2355627
were	O
homogenized	O
and	O
stained	O
for	O
histological	O
evaluation	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	I:C0178913
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	B:C0022885
and	O
stained	O
for	O
histological	O
evaluation	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	I:C0178913
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	O
and	O
stained	B:C0487602
for	O
histological	O
evaluation	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	I:C0178913
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	O
and	O
stained	O
for	O
histological	B:C0019637
evaluation	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	I:C0178913
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	O
and	O
stained	O
for	O
histological	O
evaluation	B:C0220825
.	O

Serum	B:C0229671
nitrite	O
levels	I:C0523792
were	O
lower	O
in	O
lipopolysaccharide	O
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol	O
/	O
L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
Nigella	O
sativa	I:C1140702
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
nitrite	B:C0523792
levels	I:C0523792
were	O
lower	O
in	O
lipopolysaccharide	O
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol	O
/	O
L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
Nigella	O
sativa	I:C1140702
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
nitrite	O
levels	I:C0523792
were	O
lower	O
in	O
lipopolysaccharide	B:C0023810
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol	O
/	O
L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
Nigella	O
sativa	I:C1140702
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
nitrite	O
levels	I:C0523792
were	O
lower	O
in	O
lipopolysaccharide	O
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol	O
/	O
L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
Nigella	B:C1140702
sativa	I:C1140702
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
nitrite	O
levels	I:C0523792
were	O
lower	O
in	O
lipopolysaccharide	O
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol	O
/	O
L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
Nigella	O
sativa	I:C1140702
treatment	B:C0087111
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	B:C0919829
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	B:C0919829
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	B:C1168005
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	B:C1168005
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	B:C0023810
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	B:C0919829
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	B:C1168005
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	B:C1140702
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	O
of	I:C0919829
heart	I:C0919829
interlukine	I:C0919829
-	I:C0919829
6	I:C0919829
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
)	O
and	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
(	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
)	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
compared	O
to	O
the	O
controls	O
(	O
interlukine	O
-	I:C0919829
6	I:C0919829
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg	O
/	O
mL	O
;	O
tumor	O
necrosis	I:C1168005
factor	I:C1168005
-α	I:C1168005
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
Nigella	O
sativa	I:C1140702
400	O
mg	O
/	O
kg	O
compared	O
to	O
lipopolysaccharide	B:C0023810
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	B:C0024643
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	B:C0018787
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	B:C0038734
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	B:C0038838
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	B:C0007367
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	B:C0023810
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	B:C1283255
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	B:C0087111
by	O
three	O
doses	O
of	O
Nigella	O
sativa	I:C1140702
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
Nigella	B:C1140702
sativa	I:C1140702
.	O

Histopathological	O
studies	B:C2603343
showed	O
higher	O
inflammatory	O
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	O
fibrosis	I:C1397307
,	O
and	O
collagen	O
deposition	O
in	O
lipopolysaccharide	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
Nigella	O
sativa	I:C1140702
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	B:C0541629
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	O
fibrosis	I:C1397307
,	O
and	O
collagen	O
deposition	O
in	O
lipopolysaccharide	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
Nigella	O
sativa	I:C1140702
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	B:C1397307
fibrosis	I:C1397307
,	O
and	O
collagen	O
deposition	O
in	O
lipopolysaccharide	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
Nigella	O
sativa	I:C1140702
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	O
fibrosis	I:C1397307
,	O
and	O
collagen	B:C0009325
deposition	O
in	O
lipopolysaccharide	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
Nigella	O
sativa	I:C1140702
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	O
fibrosis	I:C1397307
,	O
and	O
collagen	O
deposition	O
in	O
lipopolysaccharide	B:C0023810
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
Nigella	O
sativa	I:C1140702
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	O
fibrosis	I:C1397307
,	O
and	O
collagen	O
deposition	O
in	O
lipopolysaccharide	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	B:C3469597
of	O
Nigella	O
sativa	I:C1140702
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	I:C0541629
infiltrates	I:C0541629
,	O
cardiac	O
fibrosis	I:C1397307
,	O
and	O
collagen	O
deposition	O
in	O
lipopolysaccharide	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
Nigella	B:C1140702
sativa	I:C1140702
.	O

Treatment	B:C0087111
by	O
Nigella	O
sativa	I:C1140702
reduced	O
myocardial	O
fibrosis	I:C0151654
in	O
inflammation	O
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

Treatment	O
by	O
Nigella	B:C1140702
sativa	I:C1140702
reduced	O
myocardial	O
fibrosis	I:C0151654
in	O
inflammation	O
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

Treatment	O
by	O
Nigella	O
sativa	I:C1140702
reduced	O
myocardial	B:C0151654
fibrosis	I:C0151654
in	O
inflammation	O
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

Treatment	O
by	O
Nigella	O
sativa	I:C1140702
reduced	O
myocardial	O
fibrosis	I:C0151654
in	O
inflammation	B:C0021368
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

Treatment	O
by	O
Nigella	O
sativa	I:C1140702
reduced	O
myocardial	O
fibrosis	I:C0151654
in	O
inflammation	O
-	O
induced	O
fibrosis	B:C0016059
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

Treatment	O
by	O
Nigella	O
sativa	I:C1140702
reduced	O
myocardial	O
fibrosis	I:C0151654
in	O
inflammation	O
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	B:C0243095
balance	O
.	O

